Nuvation Bio (NUVB) Earnings Analysis

Nuvation Bio (NUVB) next reports earnings on 2026-08-06, consensus EPS -0.15 USD. Last quarter (2026-05-04) it beat with EPS 0.01 USD vs -0.02804 USD est (+135.7%). It has beaten estimates in 3/5 recent quarters (60%). Trailing P/E -15.43.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does NUVB next report earnings?

Next earnings date2026-08-06
Consensus EPS estimate-0.15 USD
Revenue estimate0.03B

NUVB earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-05-040.01 USD-0.02804 USD+135.7%Beat
2026-03-02-0.11 USD-0.11 USD0%Beat
2025-11-03-0.16 USD-0.17 USD+5.9%Beat
2025-03-06-0.15 USD-0.14 USD-7.1%Miss
2024-08-05-0.15 USD-0.06 USD-150%Miss

Beat rate: 3/5 (60%) over reported quarters with consensus data.

NUVB valuation and analyst view

Trailing P/E-15.43
Trailing EPS-0.42033 USD
Price / book7.12
Dividend yield0.00%
Market cap2.12B
Analyst consensusBuy (8 buy / 2 hold / 0 sell)
Avg price target19 USD

Related research pages

Frequently asked questions

When is Nuvation Bio (NUVB)'s next earnings date?

Nuvation Bio is next scheduled to report on 2026-08-06, with a consensus EPS estimate of -0.15 USD and revenue estimate of 0.03B.

Did NUVB beat earnings last quarter?

In its 2026-05-04 report, NUVB posted EPS of 0.01 USD versus a -0.02804 USD estimate — a beat of 135.7%.

What is NUVB's earnings track record?

Over the last 5 reported quarters with consensus data, NUVB beat estimates 3 times (60%).

What is NUVB's current P/E ratio and EPS?

NUVB trades at a trailing P/E of -15.43 on trailing EPS of -0.42032982852141465 USD.

What do analysts rate NUVB?

Analyst consensus is "Buy" across 10 ratings (0 strong buy, 8 buy, 2 hold, 0 sell, 0 strong sell). Average 12-month price target: 19 USD.